Yang Libo
Kalypsys Inc., 10420 Wateridge Circle, San Diego, CA 92121, USA.
J Control Release. 2008 Jan 22;125(2):77-86. doi: 10.1016/j.jconrel.2007.10.026. Epub 2007 Nov 12.
The fermentation of non-starch polysaccharides by colonic microflora is popular as a triggering mechanism to achieve colon-specific drug delivery in that the existence of colonic microflora is independent of gastrointestinal transit time, pH, and disease conditions, and various delivery systems were developed using this strategy. One of such delivery systems, COLAL technology, has advanced into late stage of product development. However, in vitro characterization of these delivery systems remains a challenge in part because the critical performance indicator is colonic specificity of drug release. Moreover, the dynamic and ecologically diverse features of the colon are difficult to be incorporated into USP dissolution methods. As a result, alternative dissolution approaches have been designed to better represent the colonic conditions, such as utilizing polysaccharide-degrading enzymes, rat caecal contents, human fecal slurries, and multi-stage culture systems. The primary focus of this article is to summarize and review the dissolution testing currently used in characterizing colon-specific delivery systems activated by microflora. A brief description of physiological parameters of the colon relevant to colonic drug release is also presented.
结肠微生物群对非淀粉多糖的发酵作为一种触发机制,常用于实现结肠靶向给药,因为结肠微生物群的存在与胃肠道转运时间、pH值和疾病状况无关,并且利用这一策略开发了各种给药系统。其中一种给药系统,即COLAL技术,已进入产品开发后期。然而,这些给药系统的体外特性表征仍然是一个挑战,部分原因是关键性能指标是药物释放的结肠特异性。此外,结肠动态且生态多样的特性难以纳入美国药典的溶出度测定方法中。因此,人们设计了替代溶出方法,以更好地模拟结肠条件,例如使用多糖降解酶、大鼠盲肠内容物、人粪便悬液和多级培养系统。本文的主要重点是总结和综述目前用于表征由微生物群激活的结肠靶向给药系统的溶出度测试。还简要介绍了与结肠药物释放相关的结肠生理参数。